Posted by Michael Wonder on 13 Sep 2024
Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD
12 December 2024 - Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the MHRA as an add-on maintenance treatment for chronic obstructive pulmonary disease.
The regulator’s decision specifically applies to adults with uncontrolled chronic obstructive pulmonary disease, characterised by raised blood eosinophils, and makes Dupixent the first-ever targeted biologic for uncontrolled chronic obstructive pulmonary disease in the UK.
